To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors

A Phase I Clinical Trial Evaluating the Tolerability and Pharmacokinetics of TQB2101 for Injection in Subjects With Advanced Malignancies

To explore the tolerability and pharmacokinetics of TQB2101 for injection in subjects with advanced malignant tumors.

Study Overview

• Status: Not yet recruiting
• Conditions: Breast Cancer; Colorectal Cancer; Lung Cancer
• Intervention / Treatment: Drug: TQB2101 for injection

• Study Type: Interventional
• Enrollment (Estimated): 66
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Rui Hua Xu, Doctor; Phone Number: +86 17600401750; Email: xurh@sysucc.org.cn
• Study Contact Backup: Name: Feng Wang, Doctor; Phone Number: +86 18191965905; Email: wangfeng@sysucc.org.cn

Study Locations

• China
  • Guangdong
    • Guanzhou, Guangdong, China, 510080
      • Sun Yat-sen University Cancer prevention Center
      • Contact: Rui Hua Xu, Doctor; Phone Number: +86 17600401750; Email: xurh@sysucc.org.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• The subjects voluntarily joined the study, signed the informed consent, and had good compliance;
• 18 years old ≤ age ≤75 years old (calculated on the date of signing the informed consent);
• Eastern Cooperative Oncology Group (ECOG) score 0~1;
• Expected survival greater than 12 weeks;
• Patients with advanced solid tumors confirmed by cytology/histopathology, failure of standard treatment or lack of effective treatment ; Participants with Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) -positive advanced solid tumors were enrolled in the extended study phase.
• Evidence of at least one measurable lesion according to RECIST 1.1 criteria, except that the dose-escalation phase is not required to be measurable, as long as it meets the assessment of disease status.

• The main organs function well and meet the following criteria:

  1. Hemoglobin (HGB) ≥80g/L;
  2. Absolute neutrophil count (ANC) of solid tumor subjects ≥1.5×109 /L;
  3. Platelet count (PLT) ≥100×109/L, if accompanied by bone marrow invasion, platelet ≥75×109/L;
  4. Total bilirubin (TBIL) ≤1.5 times the upper limit of normal value (ULN);
  5. Alanine transferase (ALT) and aspartate transferase (AST) ≤2.5×ULN. ALT and AST≤5×ULN if accompanied by liver metastasis;
  6. Serum creatinine (CR) ≤1.5×ULN or creatinine clearance (CCR) ≥60 mL /min (standard Cockcroft-Gault formula was applied;
  7. Prothrombin time (PT), activated partial thromboplastin time (APTT), International standardized ratio (INR) ≤ 1.5×ULN (no anticoagulant therapy);
• Women of reproductive age should agree that effective contraception must be used during the study period and for 6 months after the end of the study, and that serum or urine pregnancy tests are negative within 7 days prior to study enrollment; Men should agree that effective birth control must be used during the study period and for 6 months after the end of the study period.

Exclusion Criteria:

• Had or was currently suffering from other malignant tumors within 3 years prior to the first medication.
• There are multiple factors that affect intravenous injection, venous blood collection diseases, or have an impact on oral drugs.
• The adverse reactions of previous treatment failed to recover to Common Terminology Criteria for Adverse Events Version 5 (CTCAEv5.0) score ≤1.
• Patients who had major surgical treatment, significant traumatic injury, or potential major surgery during the expected study treatment period within 4 weeks prior to initial medication, or who had long-term unhealed wounds or fractures.
• Subjects who have had any bleeding event ≥CTCAEv5.0 level 3 within 4 weeks prior to initial dosing, or who have bleeding or clotting disease and are taking warfarin, aspirin, or other antiplatelet agglutinating agents (except maintenance doses) : Subjects with aspirin ≤100mg/ day, clopidogrel ≤75mg/ day, or with any signs of bleeding or medical history determined by the investigator to be unsuitable for enrollment.
• Patients who experienced a hyperarterial/venous thrombosis event, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis and pulmonary embolism, within 6 months before the first administration of the drug.
• Chronic hepatitis B active or active hepatitis C subjects. Subjects who are positive for hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV) antibodies during screening should undergo Hepatitis B Virus (HBV) DNA titer testing or HCV RNA testing.
• Patients with active syphilis who need treatment.
• There is a history of active pulmonary tuberculosis, idiopathic pulmonary fibrosis, institutional pneumonia, drug-induced pneumonia, radiation pneumonia requiring treatment, or active pneumonia with clinical symptoms.
• Those who have a history of psychotropic drug abuse and cannot quit or have mental disorders.
• Decompensated stage of cirrhosis and history of hepatic encephalopathy.

• Subjects with clinically significant cardiovascular disease, including any of the following:

  1. Participants who had acute myocardial infarction and severe/unstable angina pectoris within 6 months before the start of study treatment; Or have heart failure of the New York Heart Association's heart function classification level 2 or higher;
  2. QT interval prolongation at rest as corrected by Fridericia Formula (QTcF), QTc interval ≥450ms(male), QTc interval ≥470 ms(female);
  3. Have a past or ongoing history of severe uncontrolled ventricular arrhythmias requiring medical treatment;
  4. Left ventricular ejection fraction (LVEF) < 50%;
  5. Congenital long QT syndrome, or any known history of tip torsion ventricular Torsades de Pointes (TdP);
  6. Clinically uncontrolled hypertension (systolic blood pressure ≥150 mmHg and/or diastolic blood pressure ≥90 mmHg after standard antihypertensive therapy) and a history of hypertensive encephalopathy/hypertensive crisis.

Active or uncontrolled severe infection (≥CTC AEv5.0 grade 2 infection).

• Patients with renal failure requiring hemodialysis or peritoneal dialysis.
• Have a history of immunodeficiency, including HIV positivity or other acquired or congenital immunodeficiency diseases.
• Subjects with (non-infectious) pneumonia/interstitial lung disease requiring steroid treatment or who currently have non-infectious pneumonia/interstitial lung disease or have been hospitalized for any active infection or received therapeutic antibiotics in the 4 weeks prior to beginning study treatment, including but not limited to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection.
• People who have epilepsy and need treatment.
• Urine routine indicated urine protein ≥ ++, and confirmed 24-hour urine protein quantity > 1.0 g.
• Poor diabetes control (fasting blood glucose (FBG) > 10mmol/L).

• Tumor-related symptoms and treatment:

  1. For subjects who have received chemotherapy, immunotherapy within 4 weeks prior to the first dose, radiation therapy or small molecule targeted drugs within 2 weeks, or who are still within the 5 half-lives of the drug (depending on the shortest time of occurrence), the washout period is calculated from the end time of the last treatment;
  2. Within 2 weeks before the first drug use, it has been treated with Chinese patent medicines (including compound Cantharides capsule, Kangai injection, Kanglaite capsule/injection, Aidi injection, Bruceae oil injection/capsule, Xiaoaiping tablet/injection, hualbufatin capsule, etc.) with anti-tumor indications specified in the National Medical Products Administration (NMPA) approved drug instructions;
  3. Imaging (CT or MRI) shows that the tumor has invaded important blood vessels, or the investigator determines that the tumor is highly likely to invade important blood vessels during the follow-up study period and cause fatal massive bleeding;
  4. Uncontrolled pleuroceliac or pericardial effusion requiring repeated drainage or obvious symptoms. Subjects who are asymptomatic and have not received drainage or other treatment in the first 2 weeks of enrollment can be enrolled if imaging shows only small amounts of pleural effusion, ascites, or pericardial effusion.
• Known allergy to study drug excipients.
• Previous therapy with targeted ROR1 inhibitors.
• Participants who have participated in a clinical trial of another antitumor drug (calculated as the last use of the investigational drug) within 4 weeks prior to initial administration and have used the investigational drug, or are still within 5 half-lives of the investigational drug (whichever is shorter).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: TQB2101 injection; The drug was administered every 3 weeks for 21 consecutive days in a treatment cycle.	Drug: TQB2101 for injection; TQB2101 for injection is a receptor tyrosine kinase-like orphan receptor-1 antibody drug conjugate.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Phase II recommended doses (RP2D)	The dosage of drug therapy recommended for use in the second phase of clinical trials (i.e., phase II clinical trials).	Baseline up to 24 months
Dose-limiting toxicity (DLT)	Adverse events that meet the protocol definition of dose-limiting toxic event timing were evaluated according to the Common Terminology Criteria for Adverse Events 5.0.	Up to 1 month
Maximum tolerated dose (MTD)	The previous dose of the dose group in which dose-limiting toxicity occurs is the maximum tolerated dose.	Up to 1 month

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence and severity of adverse event (AE) and serious adverse event (SAE), and abnormal laboratory test indicators	Incidence and severity of AE and SAE, and abnormal laboratory test indicators	Up to 24 months
Peak time	Time to peak blood concentration after a single dose.	Up to 4 months
Peak concentration Cmax	After a single dose, the highest point of the drug-time curve is called the peak concentration.	Up to 4 months
Plasma elimination half-life t1/2	The amount of time it takes for the concentration of the drug in the blood, or the amount of drug in the body, to drop to about half of its original level.	Up to 4 months
Objective response rate	The objective response rate of injection form TQB2101 in patients with advanced solid tumors.	Up to 24 months

Collaborators and Investigators

• Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Estimated): April 1, 2025
• Primary Completion (Estimated): October 1, 2026
• Study Completion (Estimated): December 1, 2026

Study Registration Dates

• First Submitted: April 17, 2025
• First Submitted That Met QC Criteria: April 24, 2025
• First Posted (Actual): April 29, 2025

Study Record Updates

• Last Update Posted (Actual): April 29, 2025
• Last Update Submitted That Met QC Criteria: April 24, 2025
• Last Verified: December 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Intestinal Diseases; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Colonic Diseases; Colorectal Neoplasms
• Other Study ID Numbers: TQB2101-I-01

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No